Jun 18, 2026Effective9999999995-26-002066
All companies
Trade Hcw Biologics Inc
Hcw Biologics Inc
HCWBPublicArchived
Public / ArchivedUnited States(Nasdaq)Best valuation $3.91M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
HCWBPrice
$2.13
24h
-15.48%
Valuation
$3.91M
24h volume
$2.64M
Type
IPO
Trade Hcw Biologics IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 2h ago
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001828673.
Revenue
—
Net income
-$7.96M
Gross margin
—
Cash
$1.95M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | $10.85K | $959.4K | $560.36K | $2.59M | $0 |
| Operating income | -$13.16M | -$29.46M | -$25.72M | -$15.08M | -$13.37M |
| Net income | -$7.96M | -$30.02M | -$24.99M | -$14.9M | -$12.86M |
| R&D expense | $5.44M | $6.39M | $7.68M | $9.34M | $8.17M |
| Cash & equivalents | $1.95M | $4.67M | $3.6M | $22.33M | $11.73M |
| Total assets | $24.52M | $30.24M | $28.51M | $46.81M | $53.51M |
| Total liabilities | $21.76M | $37.01M | $15.05M | $9.38M | $2.32M |
| Shareholders' equity | $2.76M | -$6.77M | $13.46M | $37.43M | $51.19M |
About Hcw Biologics Inc
Hcw Biologics Inc is speculative and involves a high degree of risk.
What the company does
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
- Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Hcw Biologics Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
EffectiveEDGAR filings resolved from HCWB / CIK 0001828673.
S-1/AS-1/A
Jun 18, 2026Amended0001493152-26-029235
S-1S-1
Jun 8, 2026Filed0001493152-26-027656
Apr 29, 2026Effective9999999995-26-001391
S-1/AS-1/A
Apr 24, 2026Amended0001493152-26-018992
S-1S-1
Apr 23, 2026Filed0001493152-26-018758
Apr 13, 2026Confidential draft0001493152-26-016232
424B4424B4
Feb 19, 2026Final prospectus0001193125-26-059279
Feb 17, 2026Effective9999999995-26-000619
S-1/AS-1/A
Feb 17, 2026Amended0001193125-26-053303
S-1/AS-1/A
Feb 13, 2026Amended0001193125-26-051317
CORRESPfilename1.htm
Feb 11, 2026SEC correspondence0001193125-26-047334
Hcw Biologics Inc IPO — frequently asked questions
- When did Hcw Biologics Inc go public?
- Hcw Biologics Inc has already gone public and now trades publicly on Nasdaq under the ticker HCWB.
- Can I buy Hcw Biologics Inc stock?
- Yes — Hcw Biologics Inc is publicly traded on Nasdaq as HCWB. You can follow its live price, valuation and post-IPO performance above.
- What is Hcw Biologics Inc's valuation?
- Hcw Biologics Inc's most recent valuation tracked here is $3.91M, derived from live market prices.